# Cannabinoids in Pediatric Medicine: Evidence-Based Review > **Author:** Benjamin Caplan, MD (ABFM Board Certified, MA Lic. #240562, NPI: 1962722637) > **Publisher:** CED Clinic (https://cedclinic.com) > **Canonical URL:** https://cedclinic.com/cannabinoid-clinical-trials-pediatric-evidence-review/ > **Published:** 2026-03-06T16:00:10-04:00 | **Last Modified / Clinically Audited:** 2026-09-28T11:11:06-04:00 > **Clinical Summary:** Explore cannabinoid clinical trials pediatric evidence supporting cautious use in children with evolving safety and efficacy data. --- #### Clinical Takeaway Cannabinoids have been studied across a range of pediatric medical conditions, with evidence drawn from interventional trials, observational studies, and patient surveys. The current body of research supports cautious clinical consideration of cannabinoid therapies in children, particularly where conventional treatments have fallen short. Safety and efficacy data continue to evolve, and this living review framework ensures findings remain current as new evidence emerges. ### #2 Cannabinoids for Medical Purposes in Children: A Living Systematic Review. **Citation:** Chhabra Manik et al. *Cannabinoids for Medical Purposes in Children: A Living Systematic Review.* Acta paediatrica (Oslo, Norway: 1992). 2025. PMID: 40437694. **Study type:** Journal Article, Systematic Review  |  **Topic area:** Autism  |  **CED Score:** 13 Design: 5 Journal: 0 N: 2 Recency: 2 Pop: 3 Human: 1 Risk: 0 Why This Matters This living systematic review establishes a continuously updated evidence base on cannabinoid safety and efficacy in pediatric patients, addressing a critical knowledge gap as clinical use expands without robust pediatric safety data. The comprehensive mapping of existing literature across multiple databases provides clinicians with current evidence to inform prescribing decisions and identify priority areas for rigorous pediatric trials. By maintaining real-time synthesis of emerging evidence, this framework enables evidence-based clinical practice in a rapidly evolving therapeutic domain where pediatric-specific data remain limited. **Methodological Considerations:** - Small sample — underpowered for subgroup analysis **Abstract:** AIM: We developed a living systematic review (LSR) that will continuously map the safety and reported benefit data related to cannabinoid use for medical purposes in children. METHODS: MEDLINE, Embase, PsycInfo, and the Cochrane Library were searched from inception to April 2023. Studies involving at least one child  20% studies) in studies enrolling children were somnolence, diarrhoea, vomiting, and decreased appetite. CONCLUSION: These findings will continue to be updated to inform practice and reveal knowledge gaps for future research. Clinical Perspective This living systematic review represents a necessary effort to synthesize the sparse pediatric cannabinoid evidence base, yet clinicians should recognize that the 37,189 citations screened likely yielded a relatively modest number of actual pediatric studies, reflecting how limited the rigorous data remains outside specialized domains like childhood epilepsy. The heterogeneity of cannabinoid products, dosing regimens, and measured outcomes across included studies complicates direct comparisons and generalizability, while publication bias may overrepresent favorable findings in this emerging field. Additionally, the exclusion of mechanistic animal studies and the challenge of disentangling [cannabinoid effects](https://cedclinic.com/adolescent-cannabis-psychiatric-outcomes-2026-digest/) from confounding variables such as underlying disease severity, concurrent medications, and family expectations all warrant caution in interpretation. Until more controlled pediatric trials are completed, practitioners should view cannabinoid use in children as a potentially evidence-supported option primarily for well-established indications like refractory epilepsy, while remaining transparent with families about the gaps in safety and efficacy data for other  |   |  Further Reading Research Digest[CED Cannabis Research Digest — February 27, 2026](https://cedclinic.com/cannabis-medicine-research-digest-february-27-2026/) CED Clinic Blog[5 Essential Truths About Pediatric Cannabis Care: A Comprehensive Look](https://cedclinic.com/cannabinoids-in-pediatric-care-evidence-insights/) Cannabis Policy Wire[Policy Watch: 20 Regulatory Updates — March 10, 2026](https://cedclinic.com/dea-scheduling-synthetic-opioids-regulatory-updates-2026/) [View on PubMed ↗](https://pubmed.ncbi.nlm.nih.gov/40437694/)[Full Text ↗](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12336964/)[DOI ↗](https://doi.org/10.1111/apa.70140) RELATED READING AT CED CLINIC Continue exploring the evidence [Cannabinoids for Pediatric Medicine: Clinical Evidence Review](https://cedclinic.com/cannabinoids-pediatric-clinical-evidence-review/) A comprehensive clinical evidence review on cannabinoids used in pediatric medicine, highlighting current research and clinical insights. [Read More](https://cedclinic.com/cannabinoids-pediatric-clinical-evidence-review/) [Medical Cannabis in Pediatrics: Evidence-Based Endocannabinoid Research and Clinical Trials](https://cedclinic.com/cannabinoids-pediatric-medicine-evidence-clinical-trials/) Explore evidence-based research and [clinical trials](https://cedclinic.com/endocannabinoid-system-emotional-memory-ptsd-treatment/) on [medical cannabis](https://cedclinic.com/therapeutic-benefits-of-thc/) use in pediatric patients, focusing on [endocannabinoid system](https://cedclinic.com/endocannabinoid-system-fear-extinction/) insights. [Explore Now](https://cedclinic.com/cannabinoids-pediatric-medicine-evidence-clinical-trials/) [Cannabinoid Clinical Trials: Evidence-Based Pediatric Care](https://cedclinic.com/cannabinoid-use-pediatric-epilepsy-clinical-trials/) Review the latest evidence from cannabinoid clinical trials focused on pediatric care to inform clinical decision-making. [Discover More](https://cedclinic.com/cannabinoid-use-pediatric-epilepsy-clinical-trials/) Have thoughts on this? Share it: [X Share on X](https://twitter.com/intent/tweet?text=Cannabinoids%20in%20Pediatric%20Medicine%3A%20Evidence-Based%20Review&url=https%3A%2F%2Fcedclinic.com%2Fcannabinoid-clinical-trials-pediatric-evidence-review%2F) [in Share on LinkedIn](https://www.linkedin.com/sharing/share-offsite/?url=https%3A%2F%2Fcedclinic.com%2Fcannabinoid-clinical-trials-pediatric-evidence-review%2F) [Share on BlueSky](https://bsky.app/intent/compose?text=Cannabinoids%20in%20Pediatric%20Medicine%3A%20Evidence-Based%20Review%20https%3A%2F%2Fcedclinic.com%2Fcannabinoid-clinical-trials-pediatric-evidence-review%2F) [Follow on Instagram](https://www.instagram.com/drbenjamincaplan) [Read more on Substack](https://doctorapprovedcannabis.substack.com/) [Subscribe via RSS](https://cedclinic.com/feed/) ### Related --- ### Verification & Medical Governance - **Lead Clinical Author:** Benjamin Caplan, MD - **Credentials:** Board Certified in Family Medicine (ABFM), Founder & CMO CED Clinic & CED Foundation, Author of *The Doctor-Approved Cannabis Handbook* (Penguin Random House). - **Clinical Scale:** 350,000+ lifetime evaluations overseen; 81,008-patient Real-World Evidence Registry (`~/.ced_rwe_vault.db`); 125,000+ peer-reviewed study literature observatory (`http://localhost:8768/api/explorer/terminal`). - **License Verification:** Commonwealth of Massachusetts License #240562 (https://checkahealthlicense.mass.gov/). - **NPI Registry:** 1962722637 (https://npiregistry.cms.hhs.gov/provider-view/1962722637). - **Ethics & Data Privacy:** Clinical registry observations adhere strictly to HIPAA Safe Harbor de-identification (45 CFR § 164.514(b)) and criteria for secondary research exemption under 45 CFR § 46.104(d)(4).